Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Seelos Therapeutics Inc.

    NASDAQ: SEEL · Real-Time Price · USD
    0.37
    null (null%)
    At close: Nov 18, 2024, 9:58 PM

    Seelos Therapeutics Statistics

    Share Statistics

    Seelos Therapeutics has 581K shares outstanding. The number of shares has increased by -79.68% in one year.

    Shares Outstanding

    n/a
    		 581K

    Shares Change (YoY)

    n/a
    		 -79.68%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 370.48K

    Failed to Deliver (FTD) Shares

    n/a
    		 n/a

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -22.85 and the forward PE ratio is null. Seelos Therapeutics's PEG ratio is 0.36.

    PE Ratio

    n/a
    		 -22.85

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 392.91

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 -25.83

    P/FCF Ratio

    n/a
    		 -36.2

    PEG Ratio

    n/a
    		 0.36
    Financial Ratio History

    Enterprise Valuation

    Seelos Therapeutics has an Enterprise Value (EV) of 876.81M.

    EV / Sales

    n/a
    		 398.01

    EV / EBITDA

    n/a
    		 -23.23

    EV / EBIT

    n/a
    		 -36.67

    EV / FCF

    n/a
    		 -36.67

    Financial Position

    The company has a current ratio of 0.14, with a Debt / Equity ratio of -0.42.

    Current Ratio

    n/a
    		 0.14

    Quick Ratio

    n/a
    		 0.14

    Debt / Equity

    n/a
    		 -0.42

    Debt / EBITDA

    n/a
    		 -0.38

    Debt / FCF

    n/a
    		 -0.6

    Interest Coverage

    n/a
    		 -539.99

    Financial Efficiency

    Return on Equity is 113.05% and Return on Invested Capital is 209.87%.

    Return on Equity

    n/a
    		 113.05%

    Return on Assets

    n/a
    		 -699.19%

    Return on Invested Capital

    n/a
    		 209.87%

    Revenue Per Employee

    n/a
    		 $275,375

    Profits Per Employee

    n/a
    		 $-4,735,250

    Employee Count

    n/a
    		 8

    Asset Turnover

    n/a
    		 0.41

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by null% in the last 52 weeks. The beta is 1.94, so Seelos Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.94

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 0.88

    200-Day Moving Average

    n/a
    		 22.56

    Relative Strength Index (RSI)

    n/a
    		 31.71

    Average Volume (20 Days)

    n/a
    		 n/a

    Income Statement

    In the last 12 months, Seelos Therapeutics had revenue of 2.2M and earned -37.88M in profits. Earnings per share was -7.73.

    Revenue

    n/a
    		 2.2M

    Gross Profit

    n/a
    		 -27.91M

    Operating Income

    n/a
    		 -40.5M

    Net Income

    n/a
    		 -37.88M

    EBITDA

    n/a
    		 -37.75M

    EBIT

    n/a
    		 -37.81M

    Earnings Per Share (EPS)

    n/a
    		 -7.73
    Full Income Statement

    Balance Sheet

    The company has 3M in cash and 14.23M in debt, giving a net cash position of -11.23M.

    Cash & Cash Equivalents

    n/a
    		 3M

    Total Debt

    n/a
    		 14.23M

    Net Cash

    n/a
    		 -11.23M

    Retained Earnings

    n/a
    		 -252.63M

    Total Assets

    n/a
    		 2.38M

    Working Capital

    n/a
    		 -28.18M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -23.91M and capital expenditures 0, giving a free cash flow of -23.91M.

    Operating Cash Flow

    n/a
    		 -23.91M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -23.91M

    FCF Per Share

    n/a
    		 -4.88
    Full Cash Flow Statement

    Margins

    Gross margin is -1267.09%, with operating and profit margins of -1838.36% and -1719.56%.

    Gross Margin

    n/a
    		 -1267.09%

    Operating Margin

    n/a
    		 -1838.36%

    Pretax Margin

    n/a
    		 -1719.56%

    Profit Margin

    n/a
    		 -1719.56%

    EBITDA Margin

    n/a
    		 -1713.57%

    EBIT Margin

    n/a
    		 -1838.36%

    FCF Margin

    n/a
    		 -1085.43%

    Dividends & Yields

    SEEL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -4.38%

    FCF Yield

    n/a
    		 -2.76%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for SEEL.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 16, 2024. It was a backward split with a ratio of 1:8.

    Last Split Date

    n/a
    		 May 16, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:8

    Scores

    Altman Z-Score

    n/a
    		 -156.64

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist